SLC34A2 and ovarian neoplasm: SLC34A2 mutations in breast and thymic tumors reduce the life expectancy of patients, and SLC34A2 overexpression was found to reduce the life expectancy of patients with brain tumors, ovarian tumors, and pancreatic tumors (25).